Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 260 clinical trials
Rhenium-Skin Cancer Therapy (SCT) for the Treatment of Non-Melanoma Skin Cancer. (EPIC-Skin)

Efficacy of Personalised Irradiation with Rhenium-Skin Cancer Therapy (SCT) for the treatment of non-melanoma skin cancer; a phase IV multi-centre, international, open label, single arm study

  • 0 views
  • 20 Apr, 2022
  • 1 location
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

This is a first-in-human, multi-center clinical study to determine the safety, Maximum Tolerated Dose (MTD) and/or Optimal Biological Dose (OBD) as well as the optimal schedule for intravenous (IV) and/or subcutaneous (SC) administrations of RO7293583 with or without obinutuzumab pretreatment, in participants with unresectable metastatic TYRP1-positive melanomas who have progressed …

measurable disease
malignant melanoma of skin
mucosal melanoma
BRAF
  • 0 views
  • 17 Mar, 2022
  • 4 locations
Technology-Enabled Activation of Skin Cancer Screening for Stem Cell Transplant Survivors and Their Primary Care Providers, TEACH Study

This trial studies the impact of a 12-month invention focused on early detection of skin cancer and timely follow up in patients who underwent stem cell transplant and their primary care providers. Some stem cell transplant survivors may develop complications related to the treatment they received. Many of these complications …

allogeneic hematopoietic stem cell transplantation
cancer
skin cancer
  • 0 views
  • 10 Mar, 2022
  • 1 location
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)

RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.

squamous cell carcinoma
BRAF
measurable disease
melanoma skin
nivolumab
  • 127 views
  • 14 May, 2022
  • 44 locations
MGD019 DART® Protein in Unresectable/Metastatic Cancer

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of lorigerlimab. This Phase 1, open-label study will characterize safety, dose-limiting toxicities (DLTs), and maximum tolerated/administered dose (MTD/MAD) of MGD019. Dose escalation will occur in a 3+3+3 design in patients with …

cancer
BRAF
targeted therapy
malignant melanoma of skin
measurable disease
  • 18 views
  • 13 May, 2022
  • 29 locations
A Study of SGN-CD228A in Advanced Solid Tumors

This trial will study SGN-CD228A to find out whether it is an effective treatment for different kinds of cancer. It will also look at what side effects (unwanted effects) may occur. The study will have two parts. Part 1 of the study will find out how much SGN-CD228A should be …

progressive disease
pdac
measurable disease
metastasis
lung carcinoma
  • 16 views
  • 13 May, 2022
  • 14 locations
MoleGazer Development Feasibility Study

Melanoma (skin cancer) frequently develops from existing moles on the skin. Current practice relies on expert dermatologists being able to successfully identify new/changing moles in individuals

skin cancer screening
cancer
  • 0 views
  • 30 Sep, 2021
  • 1 location
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

This trial will look at a drug called SEA-TGT (also known as SGN-TGT) to find out whether it is safe for patients with solid tumors and lymphomas. It will study SEA-TGT to find out what its side effects are. A side effect is anything the drug does besides treating cancer. …

targeted therapy
hodgkin's disease
brentuximab vedotin
measurable disease
pembrolizumab
  • 102 views
  • 15 May, 2022
  • 29 locations
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic …

major surgery
luteinizing hormone
neutrophil count
brain metastases
dabrafenib
  • 6567 views
  • 09 May, 2022
  • 925 locations
Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma

This is a patient oriented translational research project aiming to improve clinical outcomes for patients with BRAF and NRAS wild-type unresectable Stage III or Stage IV metastatic melanoma who have progressed on, or are unable to receive standard therapy (in general, immunotherapy). Consecutive patients seen at three major clinics and …

cancer
neutrophil count
metastatic melanoma
BRAF
NRAS
  • 0 views
  • 03 Dec, 2021
  • 2 locations